Trials / Not Yet Recruiting
Not Yet RecruitingNCT06804655
Pharmacoscopy for Patients With Refractory Primary Brain Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- University of Zurich · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Advanced technology of ex vivo drug profiling referred to as pharmacoscopy may allow to identify novel drugs for the treatment of glioblastoma and other refractory brain tumors at an individual patient level. This personalized therapeutic approach was developed and validated in pre-clinical glioma models. With the current research proposal, we seek to establish feasibility for a clinical interventional trial for patients with refractory primary brain tumors that is based on pharmacoscopy-guided selection of treatment. The study is supported by an unrestricted grant from Anti Cancer Fund.
Conditions
- Brain (Nervous System) Cancers
- Glioblastoma
- Glioma
- Ependymoma
- Medulloblastoma
- Meningioma
- Rare Primary Brain Tumors
- Rare CNS Primary Tumors
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Pharmacoscopy 1.0 | The intervention is the submission of freshly obtained surgical material to ex vivo drug profiling which we term pharmacoscopy (PCY). The performance study is interventional as the test results shall influence patient management decisions and/or may be used to guide treatment. |
Timeline
- Start date
- 2026-02-12
- Primary completion
- 2028-09-15
- Completion
- 2028-09-15
- First posted
- 2025-02-03
- Last updated
- 2025-10-02
Locations
3 sites across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT06804655. Inclusion in this directory is not an endorsement.